Archivio Italiano di Urologia e Andrologia (May 2023)

Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction

  • Giovanni Maria Fusco,
  • Luigi Cirillo,
  • Francesco Mastrangelo,
  • Francesco Romano,
  • Ernesto Di Mauro,
  • Gianluigi Cacace,
  • Gianluca Spena,
  • Annamaria Iannicelli,
  • Corrado Aniello Franzese,
  • Vincenzo Mirone,
  • Roberto La Rocca,
  • Luigi Napolitano

DOI
https://doi.org/10.4081/aiua.2023.11350

Abstract

Read online

To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples’ relationship, and quality of life. [...]

Keywords